These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21447274)

  • 21. CD4(+)CD28(null) T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes.
    Moro F; Morciano A; Tropea A; Sagnella F; Palla C; Scarinci E; Cosentino N; Niccoli G; Liuzzo G; Crea F; Lanzone A; Apa R
    Fertil Steril; 2012 Dec; 98(6):1609-15. PubMed ID: 22963806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM) risk].
    Issat T; Nowicka MA; Jakimiuk AJ
    Ginekol Pol; 2015 May; 86(5):392-5. PubMed ID: 26117980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of metformin in patients with polycystic ovary syndrome: the state of the art.
    Palomba S; Falbo A; Russo T; Orio F; Tollino A; Zullo F
    Minerva Ginecol; 2008 Feb; 60(1):77-82. PubMed ID: 18277354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Gambarin-Gelwan M; Kinkhabwala SV; Schiano TD; Bodian C; Yeh HC; Futterweit W
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):496-501. PubMed ID: 17287148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stress in women: metabolic syndrome and polycystic ovary syndrome.
    Diamanti-Kandarakis E; Economou F
    Ann N Y Acad Sci; 2006 Nov; 1083():54-62. PubMed ID: 17148733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome.
    Pasquali R; Patton L; Pagotto U; Gambineri A
    Minerva Ginecol; 2005 Feb; 57(1):79-85. PubMed ID: 15758867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of glucose metabolism abnormalities in Greek women with polycystic ovary syndrome.
    Trakakis E; Basios G; Peppa M; Simeonidis G; Labos G; Creatsa M; Misailidou M; Boutati E; Vaggopoulos V; Panagopoulos P; Dimitriades G; Kassanos D
    Gynecol Endocrinol; 2012 Nov; 28(11):867-70. PubMed ID: 22571176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms of transcription factor-7-like 2 (TCF7L2) gene in Tunisian women with polycystic ovary syndrome (PCOS).
    Ben-Salem A; Ajina M; Suissi M; Daher HS; Almawi WY; Mahjoub T
    Gene; 2014 Jan; 533(2):554-7. PubMed ID: 24157263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin resistance in patients with polycystic ovary syndrome.
    Schröder AK; Tauchert S; Ortmann O; Diedrich K; Weiss JM
    Ann Med; 2004; 36(6):426-39. PubMed ID: 15513294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. To determine whether first-degree male relatives of women with polycystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitus.
    Hunter A; Vimplis S; Sharma A; Eid N; Atiomo W
    J Obstet Gynaecol; 2007 Aug; 27(6):591-6. PubMed ID: 17896258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Natural history of polycyclic ovary syndrome].
    Katulski K; Meczekalski B
    Pol Merkur Lekarski; 2010 Jul; 29(169):58-60. PubMed ID: 20712252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome.
    Espinós-Gómez JJ; Corcoy R; Calaf J
    Gynecol Endocrinol; 2009 Mar; 25(3):199-204. PubMed ID: 19347711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCOS: metabolic impact and long-term management.
    Carmina E
    Minerva Ginecol; 2012 Dec; 64(6):501-5. PubMed ID: 23232534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome.
    Skov V; Glintborg D; Knudsen S; Jensen T; Kruse TA; Tan Q; Brusgaard K; Beck-Nielsen H; Højlund K
    Diabetes; 2007 Sep; 56(9):2349-55. PubMed ID: 17563058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age.
    Pasquali R; Gambineri A
    Ann N Y Acad Sci; 2006 Dec; 1092():158-74. PubMed ID: 17308142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome.
    Sir-Petermann T; Angel B; Maliqueo M; Carvajal F; Santos JL; Pérez-Bravo F
    Diabetologia; 2002 Jul; 45(7):959-64. PubMed ID: 12136394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome.
    Hahn S; Tan S; Sack S; Kimmig R; Quadbeck B; Mann K; Janssen OE
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):130-5. PubMed ID: 17318774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
    Bizzarri C; Benevento D; Ravà L; Patera IP; Schiaffini R; Ciampalini P; Giannone G; Cappa M
    Fertil Steril; 2011 Dec; 96(6):1497-1502.e1. PubMed ID: 21982726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polycystic ovary syndrome in obese or type 1 diabetic (T1D) adolescent girls].
    Bouthors T; Elowe-Gruau É; Antoniou MC; Hryciuk J; Stoppa-Vaucher S; Ruiz Arana IL; Diserens C; Busiah K; Hauschild M
    Rev Med Suisse; 2020 Oct; 16(710):1941-1944. PubMed ID: 33058582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.